NCT01030926View on ClinicalTrials.gov

A Trial Investigating the Concentration in the Blood of NN1250 in Children, Adolescents and Adults With Type 1 Diabetes

PHASE1CompletedINTERVENTIONAL
Enrollment

39

Participants

Timeline

Start Date

December 31, 2009

Primary Completion Date

May 31, 2010

Study Completion Date

May 31, 2010

Conditions
DiabetesDiabetes Mellitus, Type 1
Interventions
DRUG

insulin degludec

0.4 U/kg body weight injected subcutaneously (under the skin), single dose

DRUG

insulin glargine

0.4 U/kg body weight injected subcutaneously (under the skin), single dose

Trial Locations (1)

30173

Novo Nordisk Investigational Site, Hanover

Sponsors

Lead Sponsor

Novo Nordisk A/S
All Listed Sponsors
lead

Novo Nordisk A/S

INDUSTRY